JINXIN FERT.GRP HD-00001 (3NX) - Total Liabilities

Latest as of December 2025: €4.76 Billion EUR ≈ $5.57 Billion USD

Based on the latest financial reports, JINXIN FERT.GRP HD-00001 (3NX) has total liabilities worth €4.76 Billion EUR (≈ $5.57 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore JINXIN FERT.GRP HD-00001 net asset momentum to track the company's year-over-year net asset growth rate.

JINXIN FERT.GRP HD-00001 - Total Liabilities Trend (2021–2025)

This chart illustrates how JINXIN FERT.GRP HD-00001's total liabilities have evolved over time, based on quarterly financial data. See 3NX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

JINXIN FERT.GRP HD-00001 Competitors by Total Liabilities

The table below lists competitors of JINXIN FERT.GRP HD-00001 ranked by their total liabilities.

Company Country Total Liabilities
Tianjin Lisheng Pharmaceutical Co Ltd
SHE:002393
China CN¥893.57 Million
Suzhou Longway Electronic Machinery Co. Ltd. A
SHE:301202
China CN¥741.06 Million
Kim Loong Resources Bhd
KLSE:5027
Malaysia RM414.07 Million
Chapters Group AG
XETRA:CHG
Germany €306.36 Million
First Hi-tec Enterprise Co Ltd
TWO:5439
Taiwan NT$7.77 Billion
Shenzhen Jiang and Associates Creative Design Co Ltd
SHE:300668
China CN¥367.47 Million
Spearhead Integrated Marketing
SHE:300071
China CN¥926.44 Million
CyberPower Systems Inc
TW:3617
Taiwan NT$4.51 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down JINXIN FERT.GRP HD-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JINXIN FERT.GRP HD-00001 market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.87 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.52 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JINXIN FERT.GRP HD-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JINXIN FERT.GRP HD-00001 (2021–2025)

The table below shows the annual total liabilities of JINXIN FERT.GRP HD-00001 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €4.76 Billion
≈ $5.57 Billion
+2.95%
2024-12-31 €4.63 Billion
≈ $5.41 Billion
-1.74%
2023-12-31 €4.71 Billion
≈ $5.51 Billion
-27.51%
2022-12-31 €6.50 Billion
≈ $7.60 Billion
+59.52%
2021-12-31 €4.07 Billion
≈ $4.76 Billion
--

About JINXIN FERT.GRP HD-00001

F:3NX Germany Medical Care Facilities
Market Cap
$712.19 Million
€609.17 Million EUR
Market Cap Rank
#10805 Global
#1259 in Germany
Share Price
€0.23
Change (1 day)
-0.85%
52-Week Range
€0.21 - €0.37
All Time High
€1.75
About

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. It offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF … Read more